Showing results (1-10 of 140) with videos related to
Sort By:
Pageof 14
Progress in Neuro-Psychopharmacology & Biological Psychiatry|April 21, 2026
MicroRNAs as potential biomarkers in schizophrenia: Current methodological limitations and challengesMar Hernaez, Eduard Parellada, Mercè BrunetPharmaceutics|March 27, 2025
Pharmacogenetic Influences on Individual Responses to Ocular Hypotensive Agents in Glaucoma PatientsSara Labay-Tejado, Virginia Fortuna, Néstor Ventura-Abreu, et al.Current Medical Research and Opinion|February 10, 2006
Clinical experience and management considerations with long-acting risperidoneEduard ParelladaPsychopharmacology Bulletin|May 22, 2007
Long-acting injectable risperidone in the treatment of schizophrenia in special patient populationsEduard ParelladaCNS Drugs|June 4, 2016
Barriers to the Use of Long-Acting Injectable Antipsychotics in the Management of SchizophreniaEduard Parellada, Miquel BioqueTranslational Psychiatry|May 7, 2021
Glutamate and microglia activation as a driver of dendritic apoptosis: a core pathophysiological mechanism to understand schizophreniaEduard Parellada, Patricia GassóExpert Review of Clinical Pharmacology|October 5, 2021
Getting immunosuppression just right: the role of clinical biomarkers in predicting patient response post solid organ transplantationMercè Brunet, Olga MillánPharmaceutics|September 23, 2022
Insights into the Pharmacogenetics of Tacrolimus Pharmacokinetics and PharmacodynamicsMercè Brunet, Marçal Pastor-AngladaTherapeutic Drug Monitoring|November 6, 2024
miRNAs, dd-cf-DNA, and Chemokines as Potential Noninvasive Biomarkers for the Assessment of Clinical Graft Evolution and Personalized Immunosuppression Requirement in Solid Organ TransplantationOlga Millán, Judit Julian, Mercè BrunetTransplantation Reviews (Orlando, Fla.)|March 21, 2009
Biomarkers of the immunomodulatory effect of immunosuppressive drugs in transplant recipientsOlga Millán, Nerea Urtasun, Mercè BrunetPageof 14